Company intelligence / Profile preview

Tautomer Bioscience

Johannesburg, Gauteng, South Africa

Ownership: Private
Development stage: Other

Overview

Tautomer has several marketed products in South Africa—especially in oncology, pain, and urology—and holds exclusive rights to develop a novel cannabinoid suppository (SBI-100) for chronic pain and other indications in Africa; regulatory filing is expected soon for chronic pain

Therapeutic areas: OphthalmologyMen's HealthInfectious DiseasesRare DiseasesCardiovascularOncologyNeurologyWomen's Health
Modalities: Small moleculeBiologicMonoclonal antibody fragmentTherapeutic enzymeBiosimilarCannabinoid-based therapeuticsHerbal medicinesNuclear medicine agentMedical device
Industry: Biotech

Partnerships

Skye Bioscience: Exclusive African license for SBI-100 THC prodrug3Sixty Global Solutions Group: Exclusive arrangement for Oncobeta nuclear medicine technology

Beyond the preview

Go deeper on Tautomer Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tautomer Bioscience.

Explore the full profile